Timing is Right for Big Pharma to Add Nuvilex Technology to Its Pipeline
Published: Mar 21, 2013
NEW YORK, NY--(Marketwire - March 21, 2013) - Nuvilex, Inc. (OTCQB: NVLX) has close to $30-million invested in its "Cell-in-a-Box" technology, and as the company gets closer to the start of its Phase III pancreatic cancer trial, the trial may be coming at just the right time!
Over the past month, Stock House Group, an investment relations firm specializing in research, content development and market awareness, has laid out a series of articles that outline how the living cell encapsulation or "Cell-in-a-Box" technology at Nuvilex can dramatically change the treatments we use for many serious, debilitating, and even fatal diseases.
From the company's clinical trials with patients suffering from advanced, inoperable, pancreatic cancer to its work in diabetes studies to create a type of "artificial pancreas" in order to eliminate the need for daily insulin requirements, to its potential to revive the excitement surrounding the use of stem cells and even to its move into the medical marijuana space which will initially focus on pancreatic cancer and cancers of the brain, Nuvilex has invested a lot of capital and time into its technology. This is time and money that has a value and price tag to a larger biotechnology or pharmaceutical company.
The fact that the company has completed two independent cancer trials and is prepping for a late-stage trial, could quite possibly leave Nuvilex sitting at just the right place, at just the right time. Earlier this year at JPMorgan's annual healthcare conference in San Francisco, Bloomberg stated in an article that the days of the big deals in the industry are back. More than 400 companies attended the conference to make their presentations, schedule one-on-one meetings and to get a sense of available and competing assets.
Continue reading the rest of this article at www.stockhousegroup.com/features
About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEOs to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we're building a library of Research to assist Investors in their due diligence on micro, small and large cap stocks.